HG-205

N/A

Report date: 2026/04/13 20:02:18

Base Information

Drug NameHG-205

Drug Alias NameMini-dCas13X RNA base editor therapy(emxABE) (HuidaGene)迷你型dCas13X-RNA碱基编辑器疗法（mxABE）HG-205HG205

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorCell and gene therapy > Gene therapy > Gene editing > RNA editingCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas13

Mechanisms of ActionOtoferlin gene transference

TargetsOtoferlin

Therapy Area/IndicationsHearing Loss

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesHuidaGene Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHuidaGene Therapeutics Co Ltd

Active IndicationsN/A

Inactive IndicationsHearing Loss

Other Information

ATC CodeN/A